Work

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.4_suppl.689

Authors: Changhoon Yoo, Hyehyun Jeong, Heejung Chae, Jaekyung Cheon, Hong Jae Chon, Hyewon Ryu, Il-Hwan Kim, Jae Ho Jeong, Kyu-Pyo Kim, Baek-Yeol Ryoo

Institutions: Asan Medical Center, University of Ulsan, Ulsan University Hospital, CHA University Bundang Medical Center, CHA University, Chungnam National University, Chungnam National University Hospital, Inje University, Inje University Haeundae Paik Hospital

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Celgene

OpenAlex ID: W3004843520

Cites:

Cited by: 1

Related to: 10